AIM ImmunoTech Sells Ampligen Business for $10M
Ticker: AIM · Form: 8-K · Filed: Jul 15, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, asset-sale, strategic-focus
TL;DR
AIM ImmunoTech selling Ampligen for $10M to focus on other drugs. Big move.
AI Summary
AIM ImmunoTech Inc. announced on July 12, 2024, that it has entered into a definitive agreement to sell its Ampligen business to a subsidiary of Grand River Pharmaceuticals for $10 million. This sale includes all intellectual property and assets related to Ampligen. The transaction is expected to close in the fourth quarter of 2024.
Why It Matters
This divestiture allows AIM ImmunoTech to focus on its other promising drug candidates, potentially streamlining its operations and financial resources for future development.
Risk Assessment
Risk Level: medium — The sale of a key asset like Ampligen could impact future revenue streams, and the success of the company now hinges more heavily on the development of its remaining pipeline.
Key Numbers
- $10.0M — Sale Price (Revenue generated from the sale of the Ampligen business.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Seller
- Ampligen (company) — Product being sold
- Grand River Pharmaceuticals (company) — Buyer
- $10 million (dollar_amount) — Sale price
- July 12, 2024 (date) — Agreement date
- fourth quarter of 2024 (date) — Expected closing date
FAQ
What is the primary reason for AIM ImmunoTech selling its Ampligen business?
AIM ImmunoTech is selling the Ampligen business to focus on its other drug candidates and streamline its operations.
Who is the buyer of the Ampligen business?
The buyer is a subsidiary of Grand River Pharmaceuticals.
What is included in the sale of the Ampligen business?
The sale includes all intellectual property and assets related to Ampligen.
When is the sale of Ampligen expected to be completed?
The transaction is expected to close in the fourth quarter of 2024.
What was the financial value of the Ampligen sale?
The definitive agreement states the sale price for the Ampligen business is $10 million.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-07-15 17:00:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-027869.txt ( ) — 203KB
- aim-20240712.xsd (EX-101.SCH) — 3KB
- aim-20240712_lab.xml (EX-101.LAB) — 33KB
- aim-20240712_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: July 15, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO